This population can be identified as erythroid-modified myeloid cells (EDMC), with the phenotype CD45+/CD235a+/CD71+/CD11b+/CD33+/HLA-DR in cancer patients and CD45+/Ter119+/CD71+/CD11b+/Gr1+ in mice with tumors. This evidence concerns the gene PTPRC and cancer.